120 related articles for article (PubMed ID: 21928002)
21. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib-associated acute pneumonitis: report of two cases.
Vahid B; Esmaili A
Can Respir J; 2007 Apr; 14(3):167-70. PubMed ID: 17464382
[TBL] [Abstract][Full Text] [Related]
23. [Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Yuba T; Nagata K; Shiotsu S; Okano A; Hatsuse M; Murakami S; Morihara K; Shimazaki C
Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):81-5. PubMed ID: 20163028
[TBL] [Abstract][Full Text] [Related]
24. [Acneiforme rash in woman with pulmonary adenocarcinoma].
Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
[No Abstract] [Full Text] [Related]
25. Erlotinib-associated alopecia in a lung cancer patient.
Costa DB; Kobayashi S; Schumer ST
J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
[No Abstract] [Full Text] [Related]
26. Erlotinib or gefitinib for non-small-cell lung cancer.
Yusuf SW; Kim P; Durand JB
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675910
[No Abstract] [Full Text] [Related]
27. Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Dallas JL; Jantz MA; Lightsey JL; Sonntag C; Kaye FJ
J Thorac Oncol; 2011 Jun; 6(6):1142-3. PubMed ID: 21623280
[No Abstract] [Full Text] [Related]
28. Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.
Onal C; Abali H; Koc Z; Kara S
Onkologie; 2012; 35(4):191-4. PubMed ID: 22488089
[TBL] [Abstract][Full Text] [Related]
29. Trichomegaly secondary to erlotinib.
Desai RU; Rachakonda LP; Saffra NA
Can J Ophthalmol; 2009 Dec; 44(6):e65. PubMed ID: 20052001
[No Abstract] [Full Text] [Related]
30. Case of erlotinib-induced photosensitivity.
Fukai T; Hasegawa T; Nagata A; Matsumura M; Kudo Y; Shiraishi E; Kamiya Y; Hirasawa Y; Ikeda S
J Dermatol; 2014 May; 41(5):445-6. PubMed ID: 24801921
[No Abstract] [Full Text] [Related]
31. [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Shi C; Han B; Gu A; Xiong L; Shen J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):529-33. PubMed ID: 21645458
[TBL] [Abstract][Full Text] [Related]
32. [Fatal interstitial lung disease associated with erlotinib use].
Eshuis M; Ahsmann EJ; van Egmond NH
Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641
[TBL] [Abstract][Full Text] [Related]
33. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Maruyama K; Chinda J; Kuroshima T; Kabara M; Nakagawa N; Fujino T; Yamamoto Y; Ohsaki Y; Ogawa Y; Hasebe N
Intern Med; 2015; 54(7):823-6. PubMed ID: 25832950
[TBL] [Abstract][Full Text] [Related]
34. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
[No Abstract] [Full Text] [Related]
35. Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Stevenson R; El-Modir A
BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688477
[TBL] [Abstract][Full Text] [Related]
36. Subacute transient encephalopathy induced by erlotinib.
Okyuama T; Akazawa Y; Uchida J; Nishino K; Kumagai T; Imamura F
Oncol Res; 2011; 19(8-9):399-402. PubMed ID: 22329199
[TBL] [Abstract][Full Text] [Related]
37. Palmar bullous blistering induced by erlotinib.
Berg A; Brustugun OT; Lund-Iversen M; Helland Å
J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
[No Abstract] [Full Text] [Related]
38. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
39. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
